[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601379":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":11,"centralContacts":36,"locations":42,"responsibleParty":256,"collaborators":11,"id":258,"slug":259,"hasResults":260,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":11,"eligibilityCriteria":263,"healthyVolunteers":260,"sex":264,"minAge":265,"maxAge":11,"enrollmentInfo":266,"targetDuration":11,"studyType":269,"phases":270,"briefSummary":273,"conditions":274,"keywords":283,"overallStatus":45,"whyStopped":11,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":296},{"fullName":5,"class":6},"Terremoto Biosciences Inc.","INDUSTRY",[8,14,19,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Monotherapy Dose Escalation","EXPERIMENTAL",null,[13],"Drug: TER-2013",{"label":15,"type":10,"description":16,"interventionNames":17},"Combination Therapy Dose Escalation","Dose Escalation of TER-2013 with recommended dose of fulvestrant",[13,18],"Drug: Fulvestrant injection",{"label":20,"type":10,"description":11,"interventionNames":21},"Monotherapy Dose Expansion",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Combination Therapy Dose Expansion","Dose Expansion of TER-2013 with recommended dose of fulvestrant",[13,18],[27,32],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":11},"DRUG","TER-2013","Oral Capsules",[15,23,9,20],{"type":28,"name":33,"description":34,"armGroupLabels":35,"otherNames":11},"Fulvestrant injection","Fulvestrant 500 mg Intramuscular Injection",[15,23],[37],{"name":38,"role":39,"phone":40,"phoneExt":11,"email":41},"Terremoto Biosciences, Inc. Clinical Trials Central Contact","CONTACT","888-682-1551","clinicaltrials@terremotobio.com",[43,62,72,87,102,117,132,145,160,175,187,200,214,226,241],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Florida Cancer Specialists - Lake Nona","RECRUITING","Orlando","Florida","32827","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-81.37924,28.53834,{"lat":55,"lon":54},[58],{"name":59,"role":39,"phone":60,"phoneExt":11,"email":61},"Elizabeth Griffith- Gilmore","904-380-2418","elizabeth.griffith@scri.com",{"facility":63,"status":45,"city":64,"state":65,"zip":66,"country":49,"countryCode":50,"cosmosGeoPoint":67,"geoPoint":71,"contacts":11},"Massachusetts General Hospital","Boston","Massachusetts","02144",{"type":52,"coordinates":68},[69,70],-71.05977,42.35843,{"lat":70,"lon":69},{"facility":73,"status":45,"city":74,"state":75,"zip":76,"country":49,"countryCode":50,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Mayo Rochester","Rochester","Minnesota","55905",{"type":52,"coordinates":78},[79,80],-92.4699,44.02163,{"lat":80,"lon":79},[83],{"name":84,"role":39,"phone":85,"phoneExt":11,"email":86},"Clinical Research Recruitment","507-284-2511","mayocliniccancerstudies@mayo.edu",{"facility":88,"status":45,"city":89,"state":90,"zip":91,"country":49,"countryCode":50,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Washington Univ. School of Medicine","St Louis","Missouri","63110",{"type":52,"coordinates":93},[94,95],-90.19789,38.62727,{"lat":95,"lon":94},[98],{"name":99,"role":39,"phone":100,"phoneExt":11,"email":101},"Study Coordinator","800-600-3606","enix@wustl.edu",{"facility":103,"status":45,"city":104,"state":105,"zip":106,"country":49,"countryCode":50,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"Nebraska Cancer Specialists","Omaha","Nebraska","68130",{"type":52,"coordinates":108},[109,110],-95.94043,41.25626,{"lat":110,"lon":109},[113],{"name":114,"role":39,"phone":115,"phoneExt":11,"email":116},"Ashley Servais Degenhardt","402-955-2691","aservais@nebraskacancer.com",{"facility":118,"status":45,"city":119,"state":120,"zip":121,"country":49,"countryCode":50,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"Carolina BioOncology Institute","Huntersville","North Carolina","28078",{"type":52,"coordinates":123},[124,125],-80.84285,35.41069,{"lat":125,"lon":124},[128],{"name":129,"role":39,"phone":130,"phoneExt":11,"email":131},"Ryan Allen","704-947-6599","info@carolinabioooncology.org",{"facility":133,"status":45,"city":134,"state":135,"zip":136,"country":49,"countryCode":50,"cosmosGeoPoint":137,"geoPoint":141,"contacts":142},"UH Cleveland Medical Center","Cleveland","Ohio","44106",{"type":52,"coordinates":138},[139,140],-81.69541,41.4995,{"lat":140,"lon":139},[143],{"name":11,"role":39,"phone":144,"phoneExt":11,"email":11},"833-788-7425",{"facility":146,"status":45,"city":147,"state":148,"zip":149,"country":49,"countryCode":50,"cosmosGeoPoint":150,"geoPoint":154,"contacts":155},"Sarah Cannon Nashville","Nashville","Tennessee","37203",{"type":52,"coordinates":151},[152,153],-86.78444,36.16589,{"lat":153,"lon":152},[156],{"name":157,"role":39,"phone":158,"phoneExt":11,"email":159},"Referral Coordinator","615.329.7274","asksarah@scresearch.net",{"facility":161,"status":45,"city":162,"state":163,"zip":164,"country":49,"countryCode":50,"cosmosGeoPoint":165,"geoPoint":169,"contacts":170},"NEXT Oncology","Austin","Texas","78229",{"type":52,"coordinates":166},[167,168],-97.74306,30.26715,{"lat":168,"lon":167},[171],{"name":172,"role":39,"phone":173,"phoneExt":11,"email":174},"Recruitment Coordinator","737-610-5200","NXTAUS_Coordinators@nextoncology.com",{"facility":176,"status":45,"city":177,"state":163,"zip":178,"country":49,"countryCode":50,"cosmosGeoPoint":179,"geoPoint":183,"contacts":184},"MD Anderson Cancer Center","Houston","77030",{"type":52,"coordinates":180},[181,182],-95.36327,29.76328,{"lat":182,"lon":181},[185],{"name":11,"role":39,"phone":186,"phoneExt":11,"email":11},"877-589-0209",{"facility":188,"status":45,"city":189,"state":163,"zip":164,"country":49,"countryCode":50,"cosmosGeoPoint":190,"geoPoint":194,"contacts":195},"START Center for Cancer Research","San Antonio",{"type":52,"coordinates":191},[192,193],-98.49363,29.42412,{"lat":193,"lon":192},[196],{"name":197,"role":39,"phone":198,"phoneExt":11,"email":199},"Isabel Jimenez","210-593-5265","isabel.jimenez@startresearch.com",{"facility":188,"status":45,"city":201,"state":202,"zip":203,"country":49,"countryCode":50,"cosmosGeoPoint":204,"geoPoint":208,"contacts":209},"West Valley City","Utah","84119",{"type":52,"coordinates":205},[206,207],-112.00105,40.69161,{"lat":207,"lon":206},[210],{"name":211,"role":39,"phone":212,"phoneExt":11,"email":213},"Marie Assay","801-907-4770","marie.asay@startresearch.com",{"facility":161,"status":45,"city":215,"state":216,"zip":217,"country":49,"countryCode":50,"cosmosGeoPoint":218,"geoPoint":222,"contacts":223},"Fairfax","Virginia","22031",{"type":52,"coordinates":219},[220,221],-77.30637,38.84622,{"lat":221,"lon":220},[224],{"name":157,"role":39,"phone":225,"phoneExt":11,"email":174},"(703) 783-4518",{"facility":227,"status":45,"city":228,"state":229,"zip":230,"country":49,"countryCode":50,"cosmosGeoPoint":231,"geoPoint":235,"contacts":236},"Froedtert & MCW Cancer Center","Milwaukee","Wisconsin","53226",{"type":52,"coordinates":232},[233,234],-87.90647,43.0389,{"lat":234,"lon":233},[237],{"name":238,"role":39,"phone":239,"phoneExt":11,"email":240},"John Charlson","414-805-8900","jcharlson@mcw.edu",{"facility":242,"status":45,"city":243,"state":11,"zip":244,"country":245,"countryCode":246,"cosmosGeoPoint":247,"geoPoint":251,"contacts":252},"PanOncology Trials","San Juan","00935","Puerto Rico","PR",{"type":52,"coordinates":248},[249,250],-66.10572,18.46633,{"lat":250,"lon":249},[253],{"name":99,"role":39,"phone":11,"phoneExt":254,"email":255},"787-407-3333","info@panoncologytrials.com",{"type":257,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100601379","phase-1-a-phase-12-trial-of-ter-2013-in-patients-with-solid-tumors-harboring-aktpi3kpten-pathway-alterations-100601379",false,"NCT07109726","A Phase 1\u002F2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT\u002FPI3K\u002FPTEN Pathway Alterations","Key Inclusion Criteria\n\n* Metastatic or locally advanced, unresectable disease\n* No available treatment with curative intent\n* Presence of lesions to be evaluated per RECIST v1.1:\n\n  a. Dose Escalation: measurable or evaluable disease b. Cohort Expansion: measurable disease\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate organ function\n* Advanced solid tumor malignancy harboring an eligible AKT\u002FPI3K\u002FPTEN pathway alteration detected by a sponsor approved test\n\nKey Inclusion Criteria for TER-2013 monotherapy arms:\n\n* Histologically confirmed diagnosis of:\n\n  a. \\[For TER-2013 dose escalation\\]: solid tumor malignancy b. \\[For TER-2013 cohort expansion\\]: i. Cohort 1: ovarian cancer, cervical cancer, or squamous cell carcinoma of the head and neck, lung, or esophagus ii. Cohort 2: endometrial adenocarcinoma\n* Prior therapy:\n\n  1. \\[For TER-2013 dose escalation\\]: Received standard therapies appropriate for their tumor type and stage, unless contraindicated, intolerable, or patient refused\n  2. \\[For TER-2013 cohort expansion\\]: No more than 3 prior lines of treatment in the advanced setting\n\n     Key Inclusion Criteria for TER-2013 and fulvestrant combination arms\n* Histologically confirmed diagnosis of:\n\n  a. \\[For TER-2013 + fulvestrant dose escalation\\]: HR+\u002FHER2- advanced unresectable or metastatic breast cancer b. \\[For TER-2013 + fulvestrant cohort expansion\\]: i. Received treatment with an AI containing regimen (single agent or in combination) ii. No more than 3 prior lines of treatment in the advanced unresectable or metastatic setting\n* Prior Therapy:\n\n  a. \\[For TER-2013 + fulvestrant dose escalation\\]: Received treatment with an AI containing regimen (single agent or in combination) b. \\[For TER-2013 + fulvestrant cohort expansion\\]: i. Received treatment with an AI containing regimen (single agent or in combination) ii. No more than 3 prior lines of treatment in the advanced unresectable or metastatic setting\n\nKey Exclusion Criteria:\n\n* Known EGFR, KRAS, NRAS, HRAS, or BRAF oncogenic-driver co-mutation with PI3K\u002FAKT\u002FPTEN alteration\n* Clinically significant abnormalities of glucose metabolism\n* Active brain metastases or carcinomatous meningitis.\n* History of significant hemoptysis or hemorrhage within 4 weeks prior to first dose of study drug\n* Malabsorption syndrome, nausea and vomiting uncontrolled by medication, or disease significantly affecting gastrointestinal function likely to interfere with the delivery, absorption, or metabolism of TER-2013\n* Prior therapy:\n\n  1. \\[For TER-2013 monotherapy escalation\\]: AKT inhibitor\n  2. \\[For TER-2013 monotherapy expansion\\]: AKT\u002FPI3K\u002FPTEN pathway inhibitor\n  3. \\[For TER-2013 + fulvestrant combination expansion\\]: AKT\u002FPI3K\u002FPTEN pathway inhibitor, fulvestrant and other SERDs, mTOR inhibitor; some PIK3CA-altered cohorts allow prior PI3K inhibitor.\n\nOther protocol-defined Inclusion\u002FExclusion Criteria apply","ALL","18 Years",{"count":267,"type":268},205,"ESTIMATED","INTERVENTIONAL",[271,272],"PHASE1","PHASE2","This is a Phase 1\u002F2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT\u002FPI3K\u002FPTEN pathway alterations.",[275,276,277,278,279,280,281,282],"Breast Cancer","Endometrial Cancer","Ovarian Cancer","Lung Squamous Cell Carcinoma","Head and Neck Squamous Cell Carcinoma","Esophageal Squamous Cell Carcinoma","Solid Tumor","Cervical Cancer",[284,275,285,286],"AKT\u002FPI3K\u002FPTEN Alterations","Advanced Solid Tumors","HR+\u002FHER2-","2026-05-20",{"date":289,"type":290},"2026-05-22","ACTUAL",{"date":292,"type":290},"2025-09-23",{"date":294,"type":268},"2029-02-28",{"name":5,"class":6},15]